Claims for Patent: 8,937,042

Summary for Patent: 8,937,042

Title:	Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide
Abstract:	Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules.
Inventor(s):	Plum; Anne (Birkerod, DK), Steensgaard; Dorte Bjerre (Copenhagen, DK), Thomsen; Jens Kaalby (Hellerup, DK), Schlein; Morten (Lyngby, DK), Markussen; Anne Sofie Kaj.ae butted.r (V.ae butted.rlose, DK), Poulsen; Christian (Copenhagen, DK)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:	12/741,923
Patent Claims:	1. A soluble pharmaceutical composition for parenteral administration, which comprises an insulinotropic GLP-1 compound, a basal insulin peptide, pharmaceutically acceptable additives and zinc, wherein the insulinotropic GLP-1 compound is Arg.sup.34, Lys.sup.26(N.sup..epsilon.-(.gamma.-Glu(N.sup..alpha.-hexadecanoyl)))-GLP- -1(7-37), wherein the basal insulin is N.sup..epsilon.B29-(N.sup..alpha.-(HOOC(CH.sub.2).sub.14CO)-.gamma.-Glu) desB30 human insulin, wherein the zinc content is between 7 and 12 Zn ions per 6 insulin molecules, and wherein the pH is between 7.7 and 8.2. 2. A pharmaceutical composition according to claim 1, wherein the concentration of the basal insulin is in the range from about 1.5 to about 8 mg/mL and the concentration of the GLP-1 compound is in the range of about 2 to about 10 mg/mL. 3. A pharmaceutical composition according to claim 1, further comprising histidine.